Advertisement

Hematologic recovery induced by eltrombopag in Japanese patients with aplastic anemia refractory or intolerant to immunosuppressive therapy

  • Hirohito YamazakiEmail author
  • Kensuke Ohta
  • Hiroatsu Iida
  • Kazunori Imada
  • Naoshi Obara
  • Yukihiro Tokumine
  • Yoshiaki Tomiyama
  • Kensuke Usuki
  • Kenji Imajo
  • Koichi Miyamura
  • Osamu Sasaki
  • Zhang Fanghong
  • Toshihiro Hattori
  • Takeshi Tajima
  • Akira Matsuda
  • Shinji Nakao
Original Article

Abstract

Eltrombopag, an oral thrombopoietin-receptor agonist, stimulates hematopoiesis in patients with acquired aplastic anemia (AA) and has higher exposure in patients of East Asian origin. We evaluated the pharmacokinetics, efficacy, and safety of eltrombopag in Japanese patients with AA refractory or intolerant to immunosuppressive therapy (IST). Twenty-one patients (15 with non-severe AA, six with severe AA) with platelet counts < 30,000/µL received eltrombopag in a dose-escalation fashion (25, 50, 75, or 100 mg once daily) depending on individual platelet responses; the responders continued eltrombopag treatment beyond 6 months. The primary endpoint was hematologic response at 6 months, defined as improvements in blood counts or transfusion requirements. Ten (48%) patients achieved hematologic responses in at least one lineage at 6 months. Six patients achieved tri- and/or bi-lineage responses with continuation of eltrombopag treatment, with two patients no longer requiring eltrombopag treatment. The most common adverse events were nasopharyngitis and abnormal hepatic function, with the majority being grade 1 or 2. Cytogenetic abnormalities were observed in three patients; however, no progression to myelodysplastic syndrome/other malignancy was observed. Eltrombopag can safely restore multi-lineage hematopoiesis in Japanese patients with AA refractory or intolerant to IST.

Clinical Trial registration NCT02148133.

Keywords

Eltrombopag Japanese patients Aplastic anemia Inter-ethnic difference 

Notes

Acknowledgements

We thank Mittal Makhija and Anamika Gulati (Novartis Healthcare Private Limited, Hyderabad, India) for providing medical writing and editorial support to draft the manuscript.

Funding

The study was funded by GlaxoSmithKline; however, as of March 2, 2015, eltrombopag is an asset of Novartis Pharma AG.

Compliance with ethical standards

Conflict of interest

HY has received grant/personal fees/non-financial support from Novartis. KO has received personal fees from Takeda, Celgene, Janssen, Bristol-Meyers Squibb, Ono, and Novartis. KI have received personal fees from Novartis, Bristol-Meyers Squibb, Takeda, Celgene, Nippon Shinyaku, MSD, Chugai, and Sumitomo Dainippon. YT received personal fees Novartis, Kyowa Hakko Kirin, and Chugai and provided advisory role to Novartis and Sysmex. HI, KM, and NO have declared no conflict of interest. KU has received grants from Astellas, AbbVie, Alexion, Gilead Sciences, SimBio, Daiichi-Sankyo, Sumitomo Dainippon, and personal fees from Novartis. TH, TT, and ZF are employees of Novartis. AM received personal fees from GlaxoSmithKline and Novartis Pharma during the conduct of the study, grants, and personal fees from Chugai, Kyowa Hakko Kirin, Sumitomo Dainippon, Nippon Shinyaku, GlaxoSmithKline, Novartis, Celgene, Alexion, Sanofi and Beckman Coulter, Shire Japan KK, Astellas, Asahi Kasei, Eisai, Otsuka, Boehringer Ingelheim, MSD, Daiichi-Sankyo, Abbvie, and HUYA Bioscience. SN has received personal fees from Novartis and Alexion.

References

  1. 1.
    Townsley DM, Desmond R, Dunbar CE, Young NS. Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes. Int J Hematol. 2013;98:48–55.CrossRefGoogle Scholar
  2. 2.
    Desmond R, Townsley DM, Dunbar C, Young NS. Eltrombopag in aplastic anemia. Semin Hematol. 2015;52:31–7.CrossRefGoogle Scholar
  3. 3.
    Lum SH, Grainger JD. Eltrombopag for the treatment of aplastic anemia: current perspectives. Drug Des Dev Ther. 2016;10:2833–43.CrossRefGoogle Scholar
  4. 4.
    Ohta A, Nagai M, Nishina M, Shimada N, Nakao S, Kurokawa M. Incidence of aplastic anemia in Japan: analysis of data from a nationwide registration system. Int J Epidemiol. 2015;44:i178.CrossRefGoogle Scholar
  5. 5.
    Bacigalupo A. How I treat acquired aplastic anemia. Blood. 2017;129:1428–36.CrossRefGoogle Scholar
  6. 6.
    Nishio N, Yagasaki H, Takahashi Y, Muramatsu H, Hama A, Yoshida N, et al. Natural history of transfusion-independent non-severe aplastic anemia in children. Int J Hematol. 2009;89:409–13.CrossRefGoogle Scholar
  7. 7.
    Locasciulli A, Oneto R, Bacigalupo A, Socié G, Korthof E, Bekassy A, et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European group for blood and marrow transplantation (EBMT). Haematologica. 2007;92:11–8.CrossRefGoogle Scholar
  8. 8.
    Marsh JCW, Kulasekararaj AG. Management of the refractory aplastic anemia patient: what are the options? Blood. 2013;122:3561–7.CrossRefGoogle Scholar
  9. 9.
    Erickson-Miller CL, Kirchner J, Aivado M, May R, Payne P, Chadderton A. Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag. Leuk Res. 2010;34:1224–31.CrossRefGoogle Scholar
  10. 10.
    Sun H, Tsai Y, Nowak I, Liesveld J, Chen Y. Eltrombopag, a thrombopoietin receptor agonist, enhances human umbilical cord blood hematopoietic stem/primitive progenitor cell expansion and promotes multi-lineage hematopoiesis. Stem Cell Res. 2012;9:77–86.CrossRefGoogle Scholar
  11. 11.
    Desmond R, Townsley DM, Dumitriu B, Olnes MJ, Scheinberg P, Bevans M, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014;123:1818–25.CrossRefGoogle Scholar
  12. 12.
    Shida Y, Takahashi N, Nohda S, Hirama T. Pharmacokinetics and pharmacodynamics of eltrombopag in healthy Japanese males. Jpn J Clin Pharmacol Ther. 2011;42:11–20.CrossRefGoogle Scholar
  13. 13.
    Gibiansky E, Zhang J, Williams D, Wang Z, Ouellet D. Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura. J Clin Pharmacol. 2011;51:842–56.CrossRefGoogle Scholar
  14. 14.
    Olnes MJ, Scheinberg P, Calvo KR, Desmond R, Tang Y, Dumitriu B, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012;367:11–9.CrossRefGoogle Scholar
  15. 15.
    Solomou EE, Rezvani K, Mielke S, Malide D, Keyvanfar K, Visconte V, et al. Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia. Blood. 2007;110:1603–6.CrossRefGoogle Scholar
  16. 16.
    Kordasti S, Marsh J, Al-Khan S, Jiang J, Smith A, Mohamedali A, et al. Functional characterization of CD4+ T cells in aplastic anemia. Blood. 2012;119:2033–43.CrossRefGoogle Scholar
  17. 17.
    Shi J, Ge M, Lu S, Li X, Shao Y, Huang J, et al. Intrinsic impairment of CD4(+) CD25(+) regulatory T cells in acquired aplastic anemia. Blood. 2012;120:1624–32.CrossRefGoogle Scholar
  18. 18.
    Dao AT, Yamazaki H, Takamatsu H, Sugimori C, Katagiri T, Maruyama H, et al. Cyclosporine restores hematopoietic function by compensating for decreased Tregs in patients with pure red cell aplasia and acquired aplastic anemia. Ann Hematol. 2016;95:771–81.CrossRefGoogle Scholar
  19. 19.
    Bao W, Bussel JB, Heck S, He W, Karpoff M, Boulad N, et al. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood. 2010;116:4639–45.CrossRefGoogle Scholar
  20. 20.
    Cheng H, Cheruku PS, Alvarado L, Cash A, Dunbar CE, Young NS, et al. Interferon-γ perturbs key signaling pathways induced by thrombopoietin, but not eltrombopag, in human hematopoietic stem/progenitor cells. Blood. 2016;128:3870.Google Scholar
  21. 21.
    Platzbecker U, Wong RS, Verma A, Abboud C, Araujo S, Chiou TJ, et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. Lancet Haematol. 2015;2:e417–26.CrossRefGoogle Scholar
  22. 22.
    Oliva EN, Alati C, Santini V, Poloni A, Molteni A, Niscola P, et al. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. Lancet Haematol. 2017;4:e127–36.CrossRefGoogle Scholar
  23. 23.
    Dickinson M, Cherif H, Fenaux P, et al. Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia. Blood. 2018;132:2629–38.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Hematology 2019

Authors and Affiliations

  • Hirohito Yamazaki
    • 1
    Email author
  • Kensuke Ohta
    • 2
  • Hiroatsu Iida
    • 3
  • Kazunori Imada
    • 4
  • Naoshi Obara
    • 5
  • Yukihiro Tokumine
    • 6
  • Yoshiaki Tomiyama
    • 7
  • Kensuke Usuki
    • 8
  • Kenji Imajo
    • 9
  • Koichi Miyamura
    • 10
  • Osamu Sasaki
    • 11
  • Zhang Fanghong
    • 12
  • Toshihiro Hattori
    • 12
  • Takeshi Tajima
    • 12
  • Akira Matsuda
    • 13
  • Shinji Nakao
    • 14
  1. 1.Division of Transfusion MedicineKanazawa University HospitalKanazawaJapan
  2. 2.Hematology Ohta ClinicOsakaJapan
  3. 3.National Hospital Organization Nagoya Medical CenterNagoyaJapan
  4. 4.Japanese Red Cross Osaka HospitalOsakaJapan
  5. 5.University of TsukubaTsukubaJapan
  6. 6.Itami City HospitalItamiJapan
  7. 7.Osaka University HospitalOsakaJapan
  8. 8.NTT Medical Center TokyoTokyoJapan
  9. 9.Okayama City HospitalOkayamaJapan
  10. 10.Japanese Red Cross Nagoya Daiichi HospitalNagoyaJapan
  11. 11.Miyagi Cancer CenterNatoriJapan
  12. 12.Novartis Pharma K.KTokyoJapan
  13. 13.International Medical CenterSaitama Medical UniversitySaitamaJapan
  14. 14.Kanazawa University Institute of Medical Pharmaceutical and Health SciencesKanazawaJapan

Personalised recommendations